These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 8612059)

  • 1. Neurobehavioral aspects of the pharmacotherapy of alcohol dependence.
    Anton RF; Kranzler HR; Meyer RE
    Clin Neurosci; 1995; 3(3):145-54. PubMed ID: 8612059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical management of alcohol dependence: clinical use and limitations of naltrexone treatment.
    Volpicelli JR; Volpicelli LA; O'Brien CP
    Alcohol Alcohol; 1995 Nov; 30(6):789-98. PubMed ID: 8679021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WHO/ISBRA Study on State and Trait Markers of Alcohol Use and Dependence: analysis of demographic, behavioral, physiologic, and drinking variables that contribute to dependence and seeking treatment. International Society on Biomedical Research on Alcoholism.
    Glanz J; Grant B; Monteiro M; Tabakoff B;
    Alcohol Clin Exp Res; 2002 Jul; 26(7):1047-61. PubMed ID: 12170115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A rational approach to the pharmacotherapy of alcohol dependence.
    Petrakis IL
    J Clin Psychopharmacol; 2006 Dec; 26 Suppl 1():S3-12. PubMed ID: 17114952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the use of naltrexone: an integration of preclinical and clinical findings.
    O'Malley SS; Froehlich JC
    Recent Dev Alcohol; 2003; 16():217-45. PubMed ID: 12638640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacological treatment of alcoholism: from basic science to clinical medicine.
    Verbanck PM
    Alcohol Alcohol; 1995 Nov; 30(6):757-64. PubMed ID: 8679016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
    Pettinati HM; O'Brien CP; Rabinowitz AR; Wortman SP; Oslin DW; Kampman KM; Dackis CA
    J Clin Psychopharmacol; 2006 Dec; 26(6):610-25. PubMed ID: 17110818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurobiology and treatment in alcoholism--recent findings regarding Lesch's typology of alcohol dependence.
    Hillemacher T; Bleich S
    Alcohol Alcohol; 2008; 43(3):341-6. PubMed ID: 18339813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent developments in alcoholism:opioid peptides.
    Froehlich JC; Li TK
    Recent Dev Alcohol; 1993; 11():187-205. PubMed ID: 7901877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-acting injectable naltrexone for the treatment of alcohol dependence.
    Mannelli P; Peindl K; Masand PS; Patkar AA
    Expert Rev Neurother; 2007 Oct; 7(10):1265-77. PubMed ID: 17939765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drugs for relapse prevention of alcoholism: ten years of progress.
    Spanagel R; Kiefer F
    Trends Pharmacol Sci; 2008 Mar; 29(3):109-15. PubMed ID: 18262663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biobehavioural basis of pharmacologic treatment of alcohol dependence.
    Sellers EM
    Alcohol Alcohol Suppl; 1994; 2():517-21. PubMed ID: 8974377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating readiness and treatment seeking effects in a pharmacotherapy trial for alcohol dependence.
    Penberthy JK; Ait-Daoud N; Breton M; Kovatchev B; DiClemente CC; Johnson BA
    Alcohol Clin Exp Res; 2007 Sep; 31(9):1538-44. PubMed ID: 17624996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The alcohol-preferring P rat and animal models of excessive alcohol drinking.
    Bell RL; Rodd ZA; Lumeng L; Murphy JM; McBride WJ
    Addict Biol; 2006 Sep; 11(3-4):270-88. PubMed ID: 16961759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.
    Gelernter J; Gueorguieva R; Kranzler HR; Zhang H; Cramer J; Rosenheck R; Krystal JH;
    Alcohol Clin Exp Res; 2007 Apr; 31(4):555-63. PubMed ID: 17374034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining psychosocial treatment with pharmacotherapy for alcohol dependence.
    Weiss RD; Kueppenbender KD
    J Clin Psychopharmacol; 2006 Dec; 26 Suppl 1():S37-42. PubMed ID: 17114954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naltrexone in the treatment of alcohol dependence: a Canadian trial.
    Romach MK; Sellers EM; Somer GR; Landry M; Cunningham GM; Jovey RD; McKay C; Boislard J; Mercier C; Pépin JM; Perreault J; Lemire E; Baker RP; Campbell W; Ryan D
    Can J Clin Pharmacol; 2002; 9(3):130-6. PubMed ID: 12422250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioid antagonists in the treatment of alcohol dependence: clinical efficacy and prevention of relapse.
    O'Malley SS
    Alcohol Alcohol; 1996 Mar; 31 Suppl 1():77-81. PubMed ID: 8737005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of endocannabinoids and cannabinoid CB1 receptors in alcohol-related behaviors.
    Hungund BL; Basavarajappa BS
    Ann N Y Acad Sci; 2004 Oct; 1025():515-27. PubMed ID: 15542757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence.
    Simpson TL; Saxon AJ; Meredith CW; Malte CA; McBride B; Ferguson LC; Gross CA; Hart KL; Raskind M
    Alcohol Clin Exp Res; 2009 Feb; 33(2):255-63. PubMed ID: 18945226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.